Behavioral alcohol use disorder therapy in early liver transplant evaluation for alcohol-associated liver disease – a multicenter retrospective cohort study

BACKGROUND: Behavioral alcohol use disorder therapy (bAUDT) is increasingly used to improve eligibility and outcomes for liver transplant (LT) among patients with alcohol-associated liver disease (ALD), especially as more centers consider LT for patients with <6 months of sobriety. This study evaluates the impacts of bAUDT in the peri-LT setting in a multicenter cohort of patients with early sobriety. METHODS: RESOLVE-ALD is a multicenter retrospective cohort study including adults with ALD and <6 months of abstinence undergoing liver transplant evaluation (LTE) between 2018-2021 at six United States LT centers. Multivariable logistic regression identified predictors of bAUDT participation during LTE and assessed its impact on LT waitlisting. Competing risk analyses examined how bAUDT affected risk of return to alcohol use pre- and post-LT. RESULTS: Among 545 patients analyzed (median sobriety time 79 days; 52.8% inpatient evaluations), 22.4% participated in bAUDT during LTE and 43% received LT. Prior alcohol-related illness (aOR=1.93, p=0.03) and heavier daily drinking (aOR=1.90, p=0.04) were associated with increased adjusted odds of bAUDT during LTE, while older age (aOR=0.41, p=0.006), underinsurance (aOR=0.42, p=0.01), and hospitalization during LTE (aOR=0.42, p=0.02) were associated with reduced adjusted odds. bAUDT participation during LTE significantly increased adjusted odds of LT waitlisting (aOR=3.40, p=0.006), but did not predict return to use pre- or post-LT. CONCLUSION: bAUDT is more common among patients with risk factors for return to use and with the medical and financial stability to participate in therapy. Although associated with increased waitlisting adjusted odds, bAUDT does not significantly predict return to alcohol use pre- or post-LT. Future research should explore optimal methods of integrating bAUDT into the LTE process to improve access and minimize barriers to LT.

Authors

Institutions

Publication Details

Journal
Liver Transplantation
Published
2026-07-27
DOI
https://doi.org/10.1097/lvt.0000000000000969
Primary Topic
Alcohol Consumption and Health Effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Behavioral alcohol use disorder therapy in early liver transplant evaluation for alcohol-associated liver disease – a multicenter retrospective cohort study

Deepika Devuni, Sasha Deutsch‐Link, Nicholas Lim, Kaleb Tesfai et al.
Liver Transplantation
Alcohol Consumption and Health Effects
article

Behavioral alcohol use disorder therapy in early liver transplant evaluation for alcohol-associated liver disease – a multicenter retrospective cohort study

Deepika Devuni, Sasha Deutsch‐Link, Nicholas Lim, Kaleb Tesfai, Anjana Rajan, Hersh Shroff, Weiyu Wu, Kawthar Mohamed, Veeral Ajmera, Chelsea Anderson, Allison Kwong, Ami Patel, Amanda Cheung, Kevin Wang, Katherine M. Cooper
article en

Abstract

BACKGROUND: Behavioral alcohol use disorder therapy (bAUDT) is increasingly used to improve eligibility and outcomes for liver transplant (LT) among patients with alcohol-associated liver disease (ALD), especially as more centers consider LT for patients with <6 months of sobriety. This study evaluates the impacts of bAUDT in the peri-LT setting in a multicenter cohort of patients with early sobriety. METHODS: RESOLVE-ALD is a multicenter retrospective cohort study including adults with ALD and <6 months of abstinence undergoing liver transplant evaluation (LTE) between 2018-2021 at six United States LT centers. Multivariable logistic regression identified predictors of bAUDT participation during LTE and assessed its impact on LT waitlisting. Competing risk analyses examined how bAUDT affected risk of return to alcohol use pre- and post-LT. RESULTS: Among 545 patients analyzed (median sobriety time 79 days; 52.8% inpatient evaluations), 22.4% participated in bAUDT during LTE and 43% received LT. Prior alcohol-related illness (aOR=1.93, p=0.03) and heavier daily drinking (aOR=1.90, p=0.04) were associated with increased adjusted odds of bAUDT during LTE, while older age (aOR=0.41, p=0.006), underinsurance (aOR=0.42, p=0.01), and hospitalization during LTE (aOR=0.42, p=0.02) were associated with reduced adjusted odds. bAUDT participation during LTE significantly increased adjusted odds of LT waitlisting (aOR=3.40, p=0.006), but did not predict return to use pre- or post-LT. CONCLUSION: bAUDT is more common among patients with risk factors for return to use and with the medical and financial stability to participate in therapy. Although associated with increased waitlisting adjusted odds, bAUDT does not significantly predict return to alcohol use pre- or post-LT. Future research should explore optimal methods of integrating bAUDT into the LTE process to improve access and minimize barriers to LT.

Liver Transplantation
University of Massachusetts Chan Medical School (US), University of Minnesota System (US), University of California San Diego (US), Durham VA Medical Center (US), University of Rochester (US), Stanford University (US)
Good health and well-being
Openalex Percentile: Top 10%
Alcohol Consumption and Health Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.